BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

23 articles for X Niu

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery and Structure Enabled Synthesis of 2,6-Diaminopyrimidin-4-one IRAK4 Inhibitors.EBI
Merck Research Laboratories
Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.EBI
Merck Research Laboratories
Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation.EBI
Merck Research Laboratories
Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4.EBI
Merck Research Laboratories
Butyrolactone I derivatives from Aspergillus terreus carrying an unusual sulfate moiety.EBI
Leibniz-Institute For Natural Product Research and Infection Biology
Structure and activity relationships of tartrate-based TACE inhibitors.EBI
Merck Research Laboratories
2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.EBI
Merck Research Laboratories
Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.EBI
Merck Research Laboratories
Biaryl substituted hydantoin compounds as TACE inhibitors.EBI
Merck Research Laboratories
Discovery and SAR of hydantoin TACE inhibitors.EBI
Merck Research Laboratories
The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.EBI
Schering-Plough Research Institute
Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.EBI
Schering-Plough Research Institute
Novel 4-Arylindolines Containing a Pyrido[3,2-EBI
Shenyang Pharmaceutical University
Discovery of 4-phenylindolines containing a (5-cyanopyridin-3-yl)methoxy moiety as potent inhibitors of the PD-1/PD-L1 interaction.EBI
Shenyang Pharmaceutical University
Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery.EBI
Peking University Shenzhen Graduate School
Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment.EBI
Southern Medical University
Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents.EBI
Southern Medical University
Efforts towards the optimization of a bi-aryl class of potent IRAK4 inhibitors.EBI
Merck Research Laboratories
Development of a prodrug of hydantoin based TACE inhibitor.EBI
Merck
Fused bi-heteroaryl substituted hydantoin compounds as TACE inhibitors.EBI
Merck
Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseasesBDB
Abbvie Deutschland
N-aralkylcarbonyl-piperazine and -homopiperazine compounds and personal care compositions comprising the sameBDB
Conopco